CHICAGO, IL – May 30, 2026 – In a presentation that has generated significant interest within the hematology and oncology community, AstraZeneca revealed compelling data from its Phase III CARES program for anselamimab, an investigational anti-fibril therapy for light chain (AL) amyloidosis. While the therapy did not meet its primary endpoint across the overall patient population, the findings presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrate a notable and clinically meaningful benefit in patients with the kappa light chain isotype. This nuanced outcome underscores the complex nature of AL amyloidosis and the potential for targeted therapeutic approaches.
The data, unveiled by AstraZeneca, focused on the performance of anselamimab within specific patient subgroups, particularly those with kappa predominant light chain isotype. This revelation comes after the company previously announced in July 2025 that the overall population of AL amyloidosis patients did not demonstrate a significant benefit from anselamimab treatment. The contrast in outcomes between the overall cohort and the kappa subgroup is a critical development, suggesting that the underlying biological mechanisms and disease progression may differ significantly based on the type of light chain involved.
Main Facts at a Glance:
- Anselamimab’s Dual Outcome: AstraZeneca’s investigational therapy, anselamimab, failed to meet its primary endpoint in the overall light chain (AL) amyloidosis patient population in the global CARES Phase III program. However, it demonstrated statistically significant and clinically meaningful benefits in a prespecified subgroup of patients with kappa predominant light chain isotype.
- Kappa Subgroup Efficacy: In a subgroup analysis of 72 patients with kappa predominant light chain isotype, anselamimab treatment, when added to standard of care (SoC) plasma cell dyscrasia (PCD) treatments, resulted in a 62% improvement in survival, measured by all-cause mortality (ACM), and a 71% reduction in cardiovascular hospitalizations (CVH) compared to placebo.
- Subgroup Survival Benefits: The observed reduction in the risk of ACM in the kappa subgroup was consistent across both trials within the CARES Phase III program, showing a 75% reduction in patients with Mayo stage IIIa disease and a 48% reduction in those with Mayo stage IIIb disease.
- Secondary Endpoints: At 50 weeks, anselamimab also showed numerical improvements in key secondary endpoints, including quality of life and functional capacity, specifically within the kappa AL amyloidosis patient group.
- Overall Population Findings: In contrast, the overall population of 328 patients, including those with the lambda isotype, did not show a mortality benefit. The mortality rate was 33.3% for those treated with anselamimab and 33.9% for placebo recipients in this broader group.
- Disease Context: AL amyloidosis is a rare, progressive disorder caused by misfolded light chain proteins that deposit in organs, leading to progressive damage and often premature death, primarily from cardiac failure.
- Regulatory Landscape: The presentation at ASCO 2026 occurs within a landscape where only one drug, Darzalex Faspro (daratumumab and hyaluronidase-fihj), is approved by the FDA for AL amyloidosis in combination with other agents.
- Broader mAb Challenges: This outcome for anselamimab follows a similar setback for Prothena’s monoclonal antibody (mAb) birtamimab, which also failed to meet its primary endpoint in a Phase III trial, leading to the discontinuation of its development in May 2025.
A Glimmer of Hope for Kappa AL Amyloidosis Patients: Detailed Data Unveiled
The ASCO 2026 presentation provided a deeper dive into the efficacy of anselamimab within the CARES program, a global clinical trial initiative that enrolled patients with Mayo stages IIIa and IIIb AL amyloidosis. The primary objective of the CARES program was to evaluate anselamimab as a first-line therapy when added to standard of care for AL amyloidosis. While the overall trial did not achieve its primary endpoint, the prespecified subgroup analysis focusing on patients with kappa predominant light chain isotype has become the focal point of discussion.
For this specific group of 72 patients, the results were striking. Anselamimab demonstrated a statistically significant and highly clinically meaningful improvement in survival, as measured by all-cause mortality (ACM). The data indicated a remarkable 62% improvement in survival for patients treated with anselamimab compared to placebo. Furthermore, the therapy significantly reduced the frequency of cardiovascular hospitalizations (CVH), a critical measure of disease burden and patient well-being in AL amyloidosis, by an impressive 71%.
The positive impact on survival was further dissected by disease stage. In patients with Mayo stage IIIa disease within the kappa subgroup, the reduction in the risk of ACM was a substantial 75%. For those with more advanced Mayo stage IIIb disease, the reduction was still significant at 48%. These figures suggest that anselamimab may offer a vital therapeutic option for patients with kappa AL amyloidosis across different stages of the disease, particularly in the challenging first-line setting.
Beyond survival and hospitalization rates, the presentation also highlighted numerical improvements in key secondary endpoints. At the 50-week mark, patients treated with anselamimab in the kappa AL amyloidosis subgroup showed positive trends in measures of quality of life and functional capacity. While these were numerical improvements and not necessarily statistically significant, they contribute to the overall picture of potential patient benefit.
The Stark Contrast: Overall Population Lacks Benefit
The promising findings in the kappa subgroup stand in stark contrast to the results observed in the overall AL amyloidosis population. As previously announced in July 2025, the Phase III CARES program, which enrolled a total of 328 patients, did not demonstrate a survival benefit for anselamimab in the broader patient group. Specifically, for the 328 patients studied, including those with the lambda isotype, the mortality rate was nearly identical between the anselamimab arm (33.3%) and the placebo arm (33.9%). This indicates that the mechanism of action or the disease pathology in patients with lambda AL amyloidosis may be less responsive to anselamimab’s anti-fibril properties.
This disparity underscores a critical aspect of AL amyloidosis: its inherent heterogeneity. The disease arises from the misfolding and aggregation of monoclonal immunoglobulin light chains, which can be either kappa or lambda isotype. The distinct physical properties and aggregation pathways of these different light chain types may influence their deposition in organs and their response to therapeutic interventions. The anselamimab data suggests that the anti-fibril mechanism of the drug may be more effective in targeting and disaggregating kappa-derived amyloid fibrils.
Understanding AL Amyloidosis: A Complex and Devastating Disorder
To fully appreciate the significance of these findings, it is essential to understand AL amyloidosis itself. It is a rare, systemic, and progressive hematologic disorder characterized by the overproduction of abnormal immunoglobulin light chains by clonal plasma cells in the bone marrow. These aberrant light chains are inherently unstable, leading to misfolding and aggregation into insoluble amyloid fibrils. These fibrils then deposit in various tissues and organs, including the heart, kidneys, liver, and nerves, causing progressive organ damage and dysfunction.
The accumulation of amyloid deposits, particularly in the heart, is the most common cause of premature death in AL amyloidosis, often leading to heart failure. The kidneys are also frequently affected, leading to renal failure. The progressive nature of the disease and the limited treatment options have historically resulted in a poor prognosis.
Chronology of Development and Presentation:
- July 2025: AstraZeneca publicly announced that the overall population of patients in the CARES Phase III program did not meet the primary endpoint for anselamimab.
- May 29 – June 1, 2026: Data from the kappa subgroup of the CARES program was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
- July 2025 (Previous Publication): The data on the full population was published in July 2025, confirming the lack of benefit in the overall cohort.
Supporting Data and Subgroup Analysis: A Closer Look
The CARES program comprised two pivotal Phase III trials: NCT04512235 for patients with Mayo stage IIIa, and NCT04504825 for those with Mayo stage IIIb. These trials were designed to evaluate anselamimab in combination with standard of care plasma cell dyscrasia (PCD) treatments. The prespecified subgroup analysis of 72 patients with kappa predominant light chain isotype was a critical component, allowing for a focused examination of the drug’s potential in a more defined patient population.
The improvement in survival by 62% in the kappa subgroup, measured by all-cause mortality (ACM), is a robust finding. ACM is a universally accepted endpoint that encompasses all causes of death, providing a comprehensive measure of treatment effect on overall survival. The concomitant 71% reduction in the frequency of cardiovascular hospitalizations (CVH) further bolsters the case for anselamimab’s efficacy in this specific patient group. Cardiovascular complications are a major driver of morbidity and mortality in AL amyloidosis, making this reduction a significant clinical achievement.
The consistent reduction in ACM risk across different disease stages within the kappa subgroup – 75% for Mayo stage IIIa and 48% for Mayo stage IIIb – is particularly encouraging. It suggests that anselamimab may be effective in both earlier and more advanced stages of kappa AL amyloidosis, offering a potential lifeline to patients who currently have limited therapeutic options.
The numerical improvements observed in key secondary endpoints at 50 weeks, including quality of life and functional capacity, further support the potential for anselamimab to positively impact the daily lives of patients with kappa AL amyloidosis. While these findings require further investigation and confirmation, they hint at a broader benefit beyond just survival.
Official Responses and Future Implications
AstraZeneca’s acquisition of Alexion, the original developer of anselamimab, in a significant deal worth up to £39 billion in 2020, has positioned the company as a major player in the rare diseases space. The company’s commitment to exploring the therapeutic potential of anselamimab, despite the initial setback in the overall population, reflects a deep understanding of the complexities of AL amyloidosis and a dedication to finding effective treatments.
The ASCO 2026 presentation signifies a crucial step in understanding where anselamimab might fit into the treatment paradigm for AL amyloidosis. While the drug may not be a panacea for all patients, its demonstrated benefit in the kappa subgroup opens the door for potential regulatory discussions and future clinical development strategies.
The current therapeutic landscape for AL amyloidosis is limited. Darzalex Faspro (daratumumab and hyaluronidase-fihj), in combination with standard chemotherapy regimens, is the only FDA-approved therapy for AL amyloidosis. This approval was based on its efficacy in reducing plasma cell burden, which indirectly impacts amyloid fibril formation. The success of anselamimab in directly targeting amyloid fibrils in a specific subgroup could offer a complementary or alternative approach.
Furthermore, the results for anselamimab add to a broader narrative of challenges faced by monoclonal antibody (mAb) approaches in AL amyloidosis. Prothena’s birtamimab, another mAb targeting amyloid deposits, also failed to meet its primary endpoint in a Phase III trial, leading to its discontinuation in May 2025. This suggests that the direct targeting of amyloid fibrils may be highly dependent on the specific isotype and potentially other patient-specific factors.
Despite these challenges, there is continued innovation in the pipeline. Immix Biopharma’s NXC-201, a novel therapy that has shown promise in relapsed/refractory AL amyloidosis and has received orphan drug designation, represents another avenue of research. The development of therapies like anselamimab, even with their specific indications, contributes valuable knowledge to the fight against this devastating disease.
The nuanced outcome of anselamimab’s Phase III trial highlights the critical importance of precision medicine in treating complex diseases like AL amyloidosis. The future of AL amyloidosis treatment may well lie in identifying specific patient subgroups based on their genetic makeup, disease characteristics, and the type of amyloid deposits, and then tailoring therapies accordingly. AstraZeneca’s ongoing commitment to exploring the full potential of anselamimab, particularly within the promising kappa subgroup, offers a beacon of hope for a disease that desperately needs more effective treatment options. The data presented at ASCO 2026 will undoubtedly fuel further research and clinical investigation into the diverse manifestations and therapeutic vulnerabilities of AL amyloidosis.
About the Author
